Creo Medical Group - CREO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 35
▼ -0.188 (-0.53%)

This chart shows the closing price for CREO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Creo Medical Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CREO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CREO

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Creo Medical Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 35.

This chart shows the closing price for CREO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Creo Medical Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/17/2023Numis SecuritiesReiterated RatingBuyGBX 100
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/28/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Creo Medical Group logo
Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.
Read More

Today's Range

Now: GBX 35
Low: 35
High: 35.50

50 Day Range

MA: GBX 35.61
Low: 32.50
High: 39.50

52 Week Range

Now: GBX 35
Low: 22.72
High: 50

Volume

320,286 shs

Average Volume

751,555 shs

Market Capitalization

£126.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Creo Medical Group?

The following equities research analysts have issued reports on Creo Medical Group in the last twelve months:
View the latest analyst ratings for CREO.

What is the current price target for Creo Medical Group?

0 Wall Street analysts have set twelve-month price targets for Creo Medical Group in the last year. has the lowest price target set, forecasting a price of £100,000 for Creo Medical Group in the next year.
View the latest price targets for CREO.

What is the current consensus analyst rating for Creo Medical Group?

Creo Medical Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CREO.

What other companies compete with Creo Medical Group?

Other companies that are similar to Creo Medical Group include EKF Diagnostics, Novacyt, NIOX Group, MaxCyte and Circassia Group. Learn More about companies similar to Creo Medical Group.

How do I contact Creo Medical Group's investor relations team?

Creo Medical Group's physical mailing address is Creo House, Unit 2, Beaufort Park Beaufort Park Way, Chepstow NP16 5UH, United Kingdom. The company's listed phone number is +44-1291-606005. The official website for Creo Medical Group is creomedical.com. Learn More about contacing Creo Medical Group investor relations.